NCT07218211 - Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

January 5, 2026

Primary Completion Date

January 5, 2027

Study Completion Date

January 5, 2028

Conditions

HIV PreventionHIV Pre-exposure ProphylaxisHIV Prevention ProgramHIV Prevention and CareHIV Pre-exposure Prophylaxis Use

Interventions

DRUG

Lenacapavir long-acting

Culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir)

Trial Locations (1)

El Centro Hispano, Durham